Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Peritoneal Cavity Cancer: early-phase trial registry

A small indexed set (8 trials) with no open enrollment listed right now.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · none currently recruiting · #2,176 of 28,707 conditions by registered trial count

Peritoneal Cavity Cancer: 8 US clinical trials tracked, none currently recruiting.

Peritoneal Cavity Cancer is the subject of 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 2 of these trials.

Enrollment posture brief

Registry condition peritoneal-cavity-cancer

OPEN 0 | RECR 0% | LATE 0 | EARLY 8 | RANK #2176 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Peritoneal Cavity Cancer (th…0%
Open-enrollment share among volume-matched conditions near Peritoneal Cavity Cancer

Peritoneal Cavity Cancer has no open enrollment in this registry pull (8 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Peritoneal Cavity Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Peritoneal Cavity Cancer is recruiting below its size-band peers.

    0 of 8 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Peritoneal Cavity Cancer research.

    City of Hope Medical Center accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Peritoneal Cavity Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 30 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.

  4. Peritoneal Cavity Cancer research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 24

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 2 52 participants

Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

City of Hope Medical Center

NCT00538031

COMPLETED Phase 2 45 participants

Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer

NYU Langone Health

NCT00005049

COMPLETED Phase 2 30 participants

Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer

Robert Morris

NCT00227721

COMPLETED Early Phase 1 29 participants

Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer

New Mexico Cancer Research Alliance

NCT01670799

COMPLETED Phase 1 27 participants

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

City of Hope Medical Center

NCT00825201

COMPLETED Phase 1 13 participants

Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Ludwig Institute for Cancer Research

NCT00803569

COMPLETED Phase 1

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Fred Hutchinson Cancer Center

NCT00217529

COMPLETED Phase 2

Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Montefiore Medical Center

NCT00030706

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 4

Named interventions

Most-linked intervention names on Peritoneal Cavity Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

carboplatin Drug
2 trials
ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine Biological
1 trials
Gemcitabine hydrochloride Drug
1 trials
liquid chromatography Other
1 trials
celecoxib Drug
1 trials
mass spectrometry Other
1 trials
ixabepilone Drug
1 trials
erlotinib hydrochloride Drug
1 trials

US sites by state

Facility locations filed on Peritoneal Cavity Cancer trials. A trial with sites in several states counts in each.

New York 3 trials
Washington 2 trials
California 2 trials
Virginia 1 trials
Ohio 1 trials
New Mexico 1 trials
Michigan 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Peritoneal Cavity Cancer page

8 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Peritoneal Cavity Cancer trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • City of Hope Medical Center sponsors the most Peritoneal Cavity Cancer trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peritoneal Cavity Cancer condition card totals 8 registered trials; most-linked intervention carboplatin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.